Legend Biotech Announces Participation in Upcoming Investor Conference

SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. Ying Huang, PhD, CEO of Legend Biotech, will participate in a fireside chat on Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time).

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005661/en/

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
[email protected]

Crystal Chen, Manager, Investor Relations, Legend Biotech
[email protected]

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech
[email protected]
(908) 331-5025

Source: Legend Biotech Corporation

You May Also Be Interested In

• Hennessy Capital Investment Corp. VII and ONE Nuclear Energy to Host Investor Update Call
• One Piece, Multiple Ways to Tackle Seasonal Temperature Swings – COOFANDY Creates a Summer-to-Fall Transitional Wardrobe Solution for Men
• Wix.com Ltd. Notice of September 22, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline